Imatinib for chronic myeloid leukemia: The impact of its effectiveness and long-term side effects

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)527-529
Number of pages3
JournalJournal of the National Cancer Institute
Volume103
Issue number7
DOIs
StatePublished - Apr 6 2011

Fingerprint

Drug Administration Schedule
Piperazines
Remission Induction
Pyrimidines
Residual Neoplasm
Survival Analysis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antineoplastic Agents
Imatinib Mesylate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{30e101048cbb488c8d4060abab308a49,
title = "Imatinib for chronic myeloid leukemia: The impact of its effectiveness and long-term side effects",
author = "Smith, {B Douglas}",
year = "2011",
month = "4",
day = "6",
doi = "10.1093/jnci/djr073",
language = "English (US)",
volume = "103",
pages = "527--529",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Imatinib for chronic myeloid leukemia

T2 - The impact of its effectiveness and long-term side effects

AU - Smith, B Douglas

PY - 2011/4/6

Y1 - 2011/4/6

UR - http://www.scopus.com/inward/record.url?scp=79953841924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953841924&partnerID=8YFLogxK

U2 - 10.1093/jnci/djr073

DO - 10.1093/jnci/djr073

M3 - Article

C2 - 21422404

AN - SCOPUS:79953841924

VL - 103

SP - 527

EP - 529

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -